TrialAmerican journal of hematology2021

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m

Neha Korde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.